By Michael Susin

Redx Pharma's lung disease treatment RCX007 has received orphan drug designation from the U.S. Food and Drug Administration for the potential treatment of idiopathic pulmonary fibrosis, the company said Monday.

The clinical-stage biotechnology company said the designation provides various development and commercial incentives, including market exclusivity, in order to address unmet demand.

The treatment is currently in a Phase 2 clinical study for IPF, with topline data expected to be released in the first quarter of 2024.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

August 21, 2023 03:02 ET (07:02 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Redx Pharma (LSE:REDX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Redx Pharma.
Redx Pharma (LSE:REDX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Redx Pharma.